Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSupernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
26.16 USD -0.58 ( 2.17%)
Last update at 2026-11-06T21:00:00Z
VOLUME
4363419
Market Cap
2403.49M

Momentum Score

…

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
25.92
Low
27.08
High
52 Week Price Range
40.51
Low
59.68
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
26.74
Dividend Yield
-
Revenue TTM
830.44M
Revenue Per Share
14.46
Gross Profit TTM
605.31M
Debt / Equity
0.04
ROE
-10.49%
Net Debt
-87.47M
ROCE
-4.40%
Diluted EPS TTM
-1.91

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -49.03M 97.87M 2.77M 60.74M 73.17M
Net income -38.55M 73.86M 1.32M 60.71M 53.42M
Selling general administrative 196.91M 247.28M 236.66M 109.43M 105.05M
Selling and marketing expenses 288.65M 88.50M 99.70M 267.79M 199.71M
Gross profit 644.39M 583.91M 523.74M 580.02M 504.71M
Reconciled depreciation 91.56M 80.41M 84.03M 82.63M 32.59M
Ebit -49.03M 97.87M 5.18M 67.30M 86.03M
Ebitda 42.53M 178.28M 90.04M 149.93M 120.06M
Depreciation and amortization 91.56M 80.41M 84.86M 82.63M 34.03M
Non operating income net other - - - 14.62M -12.85M
Operating income -36.86M 81.67M -5.27M 67.30M 86.03M
Other operating expenses 755.82M 580.15M 612.79M 621.62M 500.28M
Interest expense 0.00M 0.00M 2.42M 7.07M 23.42M
Tax provision -10.48M 24.00M 11.30M 0.03M 19.75M
Interest income 13.25M 16.20M 10.87M 21.69M 10.57M
Net interest income 13.25M 16.20M 6.86M 14.62M -12.85M
Income tax expense -10.48M 24.00M 1.45M 0.03M 19.75M
Total revenue 718.95M 661.82M 607.52M 667.24M 579.77M
Total operating expenses 681.25M 502.25M 529.01M 534.40M 425.21M
Cost of revenue 74.56M 77.91M 83.78M 87.22M 75.06M
Total other income expense net -12.17M 16.20M 8.04M -6.56M -12.85M
Net income from continuing ops -38.55M 73.86M 25.62M 60.71M 53.42M
Net income applicable to common shares - - - 60.71M 53.42M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1452.65M 1368.07M 1408.98M 1702.51M 1689.15M
Intangible assets 569.46M 521.91M 599.89M 702.46M 784.69M
Other current assets 65.33M 36.09M 16.68M 15.78M 27.02M
Total liab 390.93M 332.34M 487.46M 816.30M 873.30M
Total stockholder equity 1061.71M 1035.73M 921.52M 886.20M 815.85M
Deferred long term liab - - - 49.81M 85.36M
Other current liab 324.88M 280.92M 279.90M 139.84M 64.97M
Common stock 0.06M 0.06M 0.06M 0.05M 0.05M
Capital stock 0.06M 0.06M 0.06M 0.05M 0.05M
Retained earnings 517.88M 556.43M 482.56M 481.25M 379.92M
Other liab - - - 92.35M 137.37M
Good will 124.88M 117.02M 117.02M 117.02M 117.52M
Other assets - - - 10.90M 13.87M
Cash 128.45M 69.33M 75.05M 93.12M 203.43M
Total current liabilities 338.17M 292.40M 290.20M 687.96M 315.38M
Current deferred revenue - - 0.00M 49.81M 126.25M
Net debt -87.47M -35.06M -33.53M 344.85M 217.12M
Short term debt 10.61M 6.89M 8.33M 401.97M 6.48M
Short long term debt - - - 401.97M -
Short long term debt total 40.98M 34.27M 41.53M 437.97M 420.55M
Other stockholder equity 543.83M 479.44M 439.49M 408.12M 434.34M
Property plant equipment - - - 44.08M 52.32M
Total current assets 644.18M 686.07M 493.11M 734.15M 601.59M
Long term investments - 0.00M 16.62M 93.90M 119.17M
Net tangible assets - - - 66.72M -86.36M
Short term investments 180.22M 384.28M 179.82M 368.21M 136.25M
Net receivables 187.80M 142.08M 144.16M 165.50M 148.93M
Long term debt - - - - 379.25M
Inventory 82.39M 54.29M 77.41M 91.54M 85.96M
Accounts payable 2.68M 4.59M 1.96M 96.34M 117.68M
Accumulated other comprehensive income -0.04M -0.19M -0.59M -3.21M 1.54M
Common stock total equity - - - 0.05M 0.05M
Retained earnings total equity - - - 481.25M 379.92M
Non currrent assets other 65.25M 31.53M 8.51M -10.00M -36.12M
Non current assets total 808.47M 682.00M 915.86M 968.36M 1087.56M
Capital lease obligations 40.98M 34.27M 41.53M 36.00M 47.77M
Long term debt total - - - - 379.25M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 298.54M -189.87M 285.94M -216.25M 218.94M
Change to liabilities - - - -19.16M 18.18M
Total cashflows from investing activities 4.11M -189.87M 268.73M -216.66M -81.91M
Net borrowings 0.00M 0.00M -402.50M - -138.31M
Total cash from financing activities 9.13M 12.19M -397.88M -10.48M -130.42M
Change to operating activities - - - 29.14M -3.90M
Net income -38.55M 73.86M 1.32M 60.71M 53.42M
Change in cash 60.57M -5.72M -18.07M -110.31M -85.21M
Begin period cash flow 69.33M 75.05M 93.12M 203.43M 288.64M
End period cash flow 129.90M 69.33M 75.05M 93.12M 203.43M
Total cash from operating activities 47.33M 171.95M 111.08M 116.83M 127.13M
Issuance of capital stock 37.62M 14.91M 6.36M 12.42M 7.09M
Depreciation 90.03M 80.41M 84.86M 85.54M 32.59M
Other cashflows from investing activities -0.44M 0.01M - -0.41M -300.85M
Change to inventory -7.50M 15.81M 6.11M -17.86M -14.58M
Change to account receivables -22.30M 2.08M 18.77M -16.37M 3.87M
Sale purchase of stock - - -1.99M 12.42M 7.09M
Other cashflows from financing activities -28.49M -2.71M -1.99M -22.90M 0.80M
Change to netincome - - - -10.52M 19.62M
Capital expenditures 1.34M 0.72M 0.55M 0.41M 2.04M
Change receivables - - - -16.37M 3.87M
Cash flows other operating - - - 29.13M -3.90M
Cash and cash equivalents changes - - - -110.31M -85.21M
Change in working capital -75.16M -2.05M -9.14M -24.24M 3.57M
Stock based compensation 33.05M 27.75M 26.76M 17.57M 17.91M
Other non cash items 32.75M 12.11M 33.00M 3.57M 24.62M
Free cash flow 45.99M 171.23M 110.53M 116.41M 125.08M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SUPN
Supernus Pharmaceuticals, Inc.		 -0.58
2.17%		 26.16 - 20.16 2.89 2.34 2.51 51.86
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

9715 Key West Avenue, Rockville, MD, United States, 20850

301 838 2500

https://www.supernus.com

778

Name Title Year Born
Mr. Jack A. Khattar Founder, Pres, CEO, Sec. & Director 1961
Mr. Timothy C. Dec Sr. VP & CFO 1959
Dr. Padmanabh P. Bhatt Chief Scientific Officer & Sr. VP of Intellectual Property 1957
Ms. Tami T. Martin Sr. VP of Regulatory Affairs 1955
Dr. Jonathan Rubin Sr. VP of R&D and Chief Medical Officer 1961
Mr. Kevin T. Anderson Compliance Officer 1962
Dr. Todd Horich M.B.A., Ph.D. Sr. VP of Marketing & Market Access NA
Mr. Taylor Raiford Sr. VP of Sales NA
Dr. Bryan A. Roecklein Ph.D. Sr. VP of Corp. Devel. NA
Mr. Frank Mottola Sr. VP of Quality, GMP Operations & Information Technology 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…